 |
|
 |
Carlson, K. E., McMurry, T.J., Hunt, S.W. III . (2011) Drug Discovery Today Technologies. Pepducins: Lipopeptide allosteric modulators of GPCR signaling. Drug Discovery Today Technologies. In Press.
Janz, Jay; Ren, Yong; Looby, Richard; Kazmi, Manija; Sachdev, Pallavi; Grunbeck, Amy; Haggis, Lynn; Chinnapen, Dan; Lin, Amy; Seibert, Christoph; McMurry, Thomas; Carlson, Kenneth; Muir, Tom; Hunt III, Stephen; Sakmar, Thomas. (2011) J. Amer. Chem Soc. Direct Interaction Between an Allosteric Agonist Pepducin and the Chemokine Receptor CXCR4, J. Amer. Chem Soc. 133: 15878-81, 2011.
Dimond, P., Carlson, K., Bouvier, M., Gerard, C., Xu, L., Covic, L., Agarwal, A., Ernst, O.P., Janz, J.M., Schwartz, T.W., Gardella, T.J., Milligan, G., Kuliopulos, A., Sakmar, T.P., Hunt, S.W., (2011) Annals of the New York Academy of Science. G protein–coupled receptor modulation with pepducins: moving closer to the clinic. Volume 1226, Annals Meeting Reports pages 34–49, May 2011 DOI: 10.1111/j.1749-6632.2011.06039.x
Boris Tchernychev & Yong Ren et al. (2010) Proceedings of the National Academy of Sciences USA. Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells PNAS published ahead of print December 7, 2010, doi:10.1073/pnas.1009633108
Miller, J., Agarwal A., Devi L., Fontanini K., Hamilton J., Pin J.P., Shields D., Spek C.A., Sakmar T., Kuliopulos A., Hunt S. (2009) Annals of the New York Academy of Science. Insider access: pepducin symposium explores a new approach to GPCR modulation (p E1-E12) Published Online: Nov 18 2009 DOI: 10.1111/j.1749-6632.2009.05326.x
Yang, E., Boire, A., Agarwal, A., Nguyen, N., O’Callaghan, K., Tu, P., Kuliopulos, A., and Covic, L. (2009) Cancer Res. 69:6223-6231. Blockade of PAR1 Signaling with Cell-Penetrating Pepducins Inhibits Akt Survival Pathways in Breast Cancer Cells and Suppresses Tumor Survival and Metastasis.
Agarwal A, Covic L, Sevigny LM, Kaneider NC, Lazarides K, Azabdaftari G, Sharifi S, and Kuliopulos A. (2008) Mol Cancer Therap 7:2746-57. Targeting a Metalloprotease-PAR1 Signaling System with Cell-Penetrating Pepducins Inhibits Angiogenesis, Ascites, and Progression of Ovarian Cancer.
Kaneider, N. C., Leger, A. J., Agarwal, A., Nguyen, N., Perides, G., Derian, C., Covic, L. & Kuliopulos, A. (2007) Nat. Imm :1303-1312. Role reversal for the receptor PAR1 in sepsis-induced vascular damage.
Leger, A. J., Covic, L. & Kuliopulos, A. (2006) Circulation 114, 1070-1077. Protease-Activated Receptors in Cardiovascular Diseases.
Covic, L., Tchernychev, B., Jacques, S., & Kuliopulos, A. (2006) Handbook of Cell-Penetrating Peptides (Taylor & Francis, NY) 245-257. Pharmacology and in vivo efficacy of pepducins in hemostasis and arterial thrombosis.
Leger, A. J., Jacques, S. L., Badar, J., Kaneider, N. C., Derian, C. K., Andrade-Gordon, P., Covic, L. and Kuliopulos, A. (2006) Circulation 113:1244-54. Blocking the Protease-Activated Receptor 1-4 Heterodimer in Platelet-Mediated Thrombosis.
Swift, S., Leger, A., Talavera, J., Zhang, L., Bohm, A., and Kuliopulos, A. (2006) J. Biol. Chem. 281:4109-4116. Role of the PAR1 Receptor 8th Helix in Signaling: the 7-8-1 Receptor Activation Mechanism
Kaneider, N. C., Agarwal, A., Leger, A. & Kuliopulos, A. (2005) Nat. Med. 11:661-665. Reversing Systemic Inflammatory Response Syndrome with Chemokine Receptor Pepducins.
Boire, A., Covic, L., Agarwal, A., Jacques, A., Sherifi, S. and Kuliopulos, A. (2005) Cell 120:303-313. PAR1 is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells.
Kuliopulos, A., Covic, L. (2003) Life Sci. 74:255-262 Blocking Receptors from the Inside.
Covic L, Misra M, Badar J, Singh C, Kuliopulos A. (2002) Nat. Med. 8:1161-1165. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation.
Covic, L., Gresser, A. L., Talavera, J., Swift, S., & Kuliopulos, A. (2002) Proc. Natl. Acad. Sci. USA 99:643-648. Activation and Inhibition of G Protein-coupled Receptors by Cell-Penetrating, Membrane-Tethered Peptides. |
Selected Articles:
 |